DE3171467D1 - Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them - Google Patents

Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them

Info

Publication number
DE3171467D1
DE3171467D1 DE8181103066T DE3171467T DE3171467D1 DE 3171467 D1 DE3171467 D1 DE 3171467D1 DE 8181103066 T DE8181103066 T DE 8181103066T DE 3171467 T DE3171467 T DE 3171467T DE 3171467 D1 DE3171467 D1 DE 3171467D1
Authority
DE
Germany
Prior art keywords
preparing
inflammatory agents
steroidal anti
mannich
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8181103066T
Other languages
German (de)
English (en)
Inventor
Kenneth B Sloan
Roy Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE3171467D1 publication Critical patent/DE3171467D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8181103066T 1980-04-24 1981-04-23 Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them Expired DE3171467D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14352080A 1980-04-24 1980-04-24

Publications (1)

Publication Number Publication Date
DE3171467D1 true DE3171467D1 (en) 1985-08-29

Family

ID=22504442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8181103066T Expired DE3171467D1 (en) 1980-04-24 1981-04-23 Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them

Country Status (9)

Country Link
EP (1) EP0039051B1 (enExample)
JP (1) JPS56167643A (enExample)
AT (1) ATE14423T1 (enExample)
DE (1) DE3171467D1 (enExample)
DK (1) DK156717C (enExample)
ES (1) ES501573A0 (enExample)
GR (1) GR74496B (enExample)
IE (1) IE53001B1 (enExample)
PT (1) PT72878B (enExample)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5068251A (en) * 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US5212189A (en) * 1991-12-17 1993-05-18 Warner-Lambert Company Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
EP1542692B1 (en) 2002-05-22 2011-01-05 Amgen Inc. Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
JP4555082B2 (ja) 2002-08-08 2010-09-29 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよびそれの治療での使用
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7429616B2 (en) 2005-07-15 2008-09-30 Board Of Regents, University Of Texas System Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CN101410370B (zh) 2006-03-29 2013-06-12 诺瓦提斯公司 基于异羟肟酸酯的选择性mmp抑制剂
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
CA2656535C (en) 2006-07-14 2011-08-23 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
CA2658462C (en) 2006-07-20 2011-09-27 Amgen Inc. Substituted pyridone compounds and methods of use
WO2008009435A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
DK2207775T3 (da) 2007-11-05 2012-06-18 Novartis Ag 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose
JP5421282B2 (ja) 2007-12-03 2014-02-19 ノバルティス アーゲー 高脂血症または動脈硬化症のような疾患の処置に有用なｃｅｔｐ阻害剤としての１，２−二置換−４−ベンジルアミノ−ピロリジン誘導体
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
AU2009333214B2 (en) 2008-12-17 2013-09-26 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010085968A1 (en) 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
WO2010075869A1 (en) 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
BRPI1011657A2 (pt) 2009-05-28 2019-04-16 Novartis Ag derivados aminopropiônicos substituídos como inibidores de neprilisina
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
WO2010151791A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
IN2012DN02493A (enExample) 2009-09-03 2015-08-28 Allergan Inc
EP2473502A1 (en) 2009-09-04 2012-07-11 Novartis AG Heteroaryl compounds as kinase inhibitors
US20110130380A1 (en) 2009-09-04 2011-06-02 Barsanti Paul A Heteroaryl Kinase Inhibitors
CN102482265A (zh) 2009-09-04 2012-05-30 诺瓦提斯公司 用于治疗增殖性疾病的吡嗪基吡啶化合物
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
WO2011061168A1 (en) 2009-11-17 2011-05-26 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
AU2010330875B2 (en) 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses
CN102762560A (zh) 2009-12-21 2012-10-31 诺瓦提斯公司 二取代的杂芳基-稠合的吡啶
US8530648B2 (en) 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
MX2012013128A (es) 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
WO2011143366A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
EP2582680A1 (en) 2010-06-17 2013-04-24 Novartis AG Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
MX2012014983A (es) 2010-06-30 2013-04-24 Amgen Inc Quinolinas como inhibidores pi3k.
MX2012015143A (es) 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
EP2588471A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US20130085131A1 (en) 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
ES2472720T3 (es) 2010-07-01 2014-07-02 Amgen Inc. Compuestos heteroc�clicos y su uso como inhibidores de actividad PI3K
CA2803624A1 (en) 2010-07-02 2012-01-05 Jason A. Duquette Heterocyclic compounds and their use as inhibitors of pi3k activity
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
PL2483255T3 (pl) 2010-07-13 2014-03-31 Novartis Ag Pochodne oksazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
CA2806108A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
RS54544B1 (sr) 2010-09-13 2016-06-30 Novartis Ag Triazin-oksadiazoli
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012040230A1 (en) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
MX2013005005A (es) 2010-11-04 2013-10-25 Amgen Inc Derivados de ciano-4,6-diaminopirimidina o 6-aminopurina como inhibidores de pi3k-delta.
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
AU2011329806A1 (en) 2010-11-17 2013-05-30 Amgen Inc. Quinoline derivatives as PIK3 inhibitors
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012087521A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
MX2013007261A (es) 2010-12-23 2013-11-04 Amgen Inc Compuestos heterociclicos y sus usos.
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
BR112013017988A2 (pt) 2011-01-13 2019-09-24 Novartis Ag inibidores de bace-2 para o tratamento de distúrbios metabólicos
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CA2834166A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EP2768813A1 (en) 2011-10-21 2014-08-27 Novartis AG Quinazoline derivatives as pi3k modulators
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
HUE028762T2 (en) 2012-04-04 2016-12-28 Amgen Inc Heterocyclic compounds and their applications
KR20150003903A (ko) 2012-05-04 2015-01-09 노파르티스 아게 보체 경로 조절제 및 그의 용도
US20150152083A1 (en) 2012-06-06 2015-06-04 Irm Llc, A Delaware Limited Liability Company Compounds and Compositions for Modulating EGFR Activity
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
AR091436A1 (es) 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
MX2014015738A (es) 2012-06-28 2015-08-06 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
AU2016236187B2 (en) 2015-03-24 2020-05-21 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Inhibitors of Pseudomonas aeruginosa LecB
EP3288948B1 (en) 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
AU2016308568A1 (en) 2015-08-19 2018-02-22 Vivus Llc Pharmaceutical formulations
CN105418480B (zh) * 2015-11-16 2019-05-10 青岛大学 2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
MX378012B (es) 2015-12-18 2025-03-10 Amgen Inc Compuestos de alquinil dihidroquinolina sulfonamida.
EA038286B1 (ru) 2015-12-18 2021-08-04 Амген Инк. Соединения алкилдигидрохинолинсульфонамида
CA3051986A1 (en) 2017-02-10 2018-08-16 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
AU2018285450A1 (en) 2017-06-14 2019-12-19 European Molecular Biology Laboratory Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
JP2020523363A (ja) 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のための二環式複素芳香族アミド化合物
AU2018285449A1 (en) 2017-06-14 2019-12-19 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
US20210147405A1 (en) 2017-06-14 2021-05-20 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
CA3088326A1 (en) 2018-02-06 2019-08-15 Universitat Heidelberg Fap inhibitor
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
JP7756070B2 (ja) 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MX2022001295A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
JP2023501323A (ja) 2019-11-05 2023-01-18 へルムホルツ－ツェントルム・フューア・インフェクツィオーンスフォルシュング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 緑膿菌のバイオフィルム形成を標的とする二価のＬｅｃＡ阻害薬
MX2022008931A (es) 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composiciones farmaceuticas y sus usos.
MX2022008930A (es) 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composiciones farmaceuticas y sus usos.
AU2021257801A1 (en) 2020-04-14 2022-10-27 Amgen Inc. KIF18A inhibitors for treatment of neoplastic diseases
WO2021234181A1 (en) 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
AU2021288190A1 (en) 2020-06-10 2022-12-22 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
US20240025849A1 (en) 2020-08-26 2024-01-25 Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Inhibitors of no production
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
JP2023554396A (ja) 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
JP2024541991A (ja) 2021-10-29 2024-11-13 アイスバッハ・バイオ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規アロステリック結合部位に結合するウイルスヘリカーゼ阻害剤
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法
JP2025515110A (ja) 2022-05-02 2025-05-13 アイスバッハ・バイオ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ａｌｃ１阻害剤の使用およびｐａｒｐｉとの相乗作用
WO2024022332A1 (en) 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors
US20250034117A1 (en) 2023-07-12 2025-01-30 HMNC Holding GmbH Deuterated 1,3 Dihydro -2H-indole-2-one derivatives
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
CN120202191A (zh) 2023-09-12 2025-06-24 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
TW202535405A (zh) 2023-10-25 2025-09-16 德商艾斯巴赫生物有限公司 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑
WO2025088087A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
WO2025093706A1 (en) 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3417096A (en) * 1965-07-01 1968-12-17 Bristol Myers Co Certain 5(1-benzoyl-3-indolylmethyl) tetrazoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
NO134946C (enExample) * 1970-09-09 1977-01-12 Ciba Geigy Ag
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
EP0039051A3 (en) 1982-05-26
EP0039051B1 (en) 1985-07-24
JPS56167643A (en) 1981-12-23
JPH04982B2 (enExample) 1992-01-09
EP0039051A2 (en) 1981-11-04
ES8207508A1 (es) 1982-09-16
DK156717B (da) 1989-09-25
PT72878A (en) 1981-05-01
IE810899L (en) 1981-10-24
GR74496B (enExample) 1984-06-28
ATE14423T1 (de) 1985-08-15
DK156717C (da) 1990-02-19
IE53001B1 (en) 1988-05-11
ES501573A0 (es) 1982-09-16
DK182081A (da) 1981-10-25
PT72878B (en) 1983-03-29

Similar Documents

Publication Publication Date Title
DE3171467D1 (en) Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them
HU9300759D0 (en) Method for producing triazolo-pyridine derivatives and pharmaceutical preparatives containing said compounds as active substance
ES8103093A1 (es) Un procedimiento para preparar derivados de oxapenem
GR77296B (enExample)
PH24176A (en) New bicyclic compounds,process for preparation thereof and pharmaceutical composition comprising the same
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
ATE54450T1 (de) Thiazolylessigsaeure-derivate und verfahren zu deren herstellung.
US2844510A (en) Phosphoric acid derivatives of 1-phenyl-2, 3-dimethyl-4-amino-5-pyrazolone
HU910748D0 (en) New substituted amine compounds and process for producing them
IE780901L (en) Tetrazolyl-piperidinyl amides
MA18964A1 (fr) 2-aminoalkyl-5-pyridinols,procede pour leur preparation,compositions pharmaceutiques contenant ces composes et leurs utilisations therapeutiques
IL40312A (en) 1,3-dihydro-5-phenyl-2h-1,4-benzodiazepin-2-one derivatives,processes for their preparation and pharmaceutical compositions containing them
ES8105286A1 (es) Un procedimiento para la preparacion de nuevos derivados de dihidropiridina.
DE3063105D1 (en) Clavulanic acid derivatives, process for their preparation and pharmaceutical compositions containing them
GB1080128A (en) Method of producing new nicotinic acid esters

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee